Trial · NCT03680911
NAC for Head Trauma-induced Anosmia
NCT03680911, Phase 3, Terminated, University of Miami; results first posted 2021-02-04
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. NAC for Head Trauma-induced Anosmia. Trials, record NCT03680911. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03680911
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- NAC for Head Trauma-induced Anosmia
- NCT number
- NCT03680911
- Status
- Terminated
- Phases
- Phase 3
- Enrollment
- 7 participants, actual
- Lead sponsor
- University of Miami
- Conditions
- Anosmia, Head Trauma
- Interventions
- N Acetyl Cysteine, Placebo oral capsule
- First posted
- 2018-09-21
- Last updated
- 2021-02-04
- Results first posted
- 2021-02-04
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Olfactory Function | 4 months | Olfactory function will be measured using the University of Pennsylvania Smell Identification Test (UPSIT). The UPSIT is a self-administered 40-item test involving microencapsulated (scratch-and-sniff) odors with a forced-choice design. The total score ranges from 0-40 with the higher score indicating better olfactory function. |
| Secondary | Quality of Life Questionnaire | 4 months | Quality of life will be measured using the questionnaire for Olfactory Disorders (QOD). QOD has a total score from 0-75 with the higher score indicating a better quality of life. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Olfactory Function | 4 months | Data will not be reported due to confidentiality, there was only one participant to complete the 1 month follow up visit. Study was terminated prior to the remaining participants completing any follow up visits as per protocol. | ||
| SECONDARY | Quality of Life Questionnaire | 4 months | Data will not be reported due to confidentiality, there was only one participant to complete the 1 month follow up visit. Study was terminated prior to the remaining participants completing any follow up visits as per protocol. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow24
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Visit 1 (Baseline) | STARTED | NAC Group | 3 | |
| Visit 1 (Baseline) | STARTED | Placebo Group | 4 | |
| Visit 1 (Baseline) | COMPLETED | NAC Group | 3 | |
| Visit 1 (Baseline) | COMPLETED | Placebo Group | 4 | |
| Visit 1 (Baseline) | NOT COMPLETED | NAC Group | 0 | |
| Visit 1 (Baseline) | NOT COMPLETED | Placebo Group | 0 | |
| At Home Treatment | STARTED | NAC Group | 3 | |
| At Home Treatment | STARTED | Placebo Group | 4 | |
| At Home Treatment | COMPLETED | NAC Group | 0 | |
| At Home Treatment | COMPLETED | Placebo Group | 1 |
1 to 10 of 24Source ClinicalTrials.gov
See all 24 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | NAC Group | 0 | 3 |
| Total, all-cause mortality | Placebo Group | 0 | 4 |
| Total, other adverse events | NAC Group | 0 | 3 |
| Total, other adverse events | Placebo Group | 0 | 4 |
| Total, serious adverse events | NAC Group | 0 | 3 |
| Total, serious adverse events | Placebo Group | 0 | 4 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| NAC Group vs Placebo Group: deaths from any cause | Trial comparisons |
| NAC Group vs Placebo Group: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03680911
GET https://conductscience.org/api/trials/v1/NCT03680911/flow?page=2